When Will Iambic Therapeutics IPO? $15 to $17 Proposed Range

By Segmara Research · Published · Updated

Start from $25 → · Request Iambic Therapeutics Allocation → · Stripe checkout (Card, Apple Pay, Link · no password · terms).

Just researching? Get free Iambic Therapeutics mark alerts by email

Free tracker, email only. No card, no documents. Or start from $25 on Stripe →

As of October 8, 2026, Iambic Therapeutics has proposed an IPO of 9,375,000 shares at $15 to $17 per share. Its first amended S-1, filed that day, adds these terms to the registration statement first filed on September 21. Iambic has applied to list on the Nasdaq Global Select Market as IAM, and the offering depends on listing approval. The prospectus is preliminary: its final price and share-delivery date remain blank. J.P. Morgan, Jefferies, BofA Securities and Citigroup are the underwriters. Segmara does not sell, broker or arrange Iambic shares and does not predict a pricing or listing date.

Pre-IPO Allocation: Start Iambic Therapeutics from $25 via Stripe or explore 140+ live pre-IPO listings →

Educational pre-IPO guide. Share allocations and secondary transactions are subject to eligibility and private settlement terms.

Start Iambic Therapeutics from $25 →

Key points

What changed in the October 8 filing

The amended S-1 proposes 9,375,000 shares at $15 to $17 each, replacing the blank offering terms in the original September 21 filing. The underwriters also have a 30-day option to buy up to 1,406,250 additional shares.

Iambic has applied to list on the Nasdaq Global Select Market under IAM. The prospectus remains subject to completion, the offering depends on listing approval, and the final price and share-delivery date are blank. The proposed range does not establish a first trading date.

What the filing says about IAM1363

IAM1363 is an oral small-molecule inhibitor of HER2. The amended S-1 describes an ongoing, open-label Phase 1/1b basket trial in patients with advanced HER2-altered solid tumors.

Iambic says it anticipates starting a registrational trial as early as 2027, subject to regulatory feedback. That is the company's plan, not a trial result or a regulatory decision.

Use of proceeds and finances

Iambic estimates net proceeds of $135.0 million at the assumed $16 midpoint, after underwriting discounts, commissions and offering expenses, without the additional-share option. It plans to use the proceeds and existing cash for IAM1363, IAM217 and IAM-C1 development, its research platform, working capital and other corporate purposes.

The amended S-1 reports net losses of $77.3 million in 2025 and $50.1 million in the first half of 2026, with an accumulated deficit of $245.3 million at June 30, 2026.

Private-share data lens

Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.

Segmara markNo indicative price yet

Indicative listing context

StageDateValuation / price signalWhy it matters
Seed / earlyPrivateNot reliably publicDo not invent a seed price when the source set is thin.
Growth roundsPrivateCompany and market sources varyUse public sources and official company releases.
Segmara listingCurrentNo indicative price yetIndicative reference only, not a quote or an offer.
IPO statusCurrentNo public ticker shown hereWatch official company releases and the free Segmara IPO calendar.

Seed-to-IPO path

Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.

Early data22%
Growth data46%
Segmara mark68%
IPO/public18%
Start Iambic Therapeutics from $25 →

AI-ready data summary

A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.

MetricValueContext
Canonical route/blog/when-will-iambic-therapeutics-ipoStable URL path for AI and search extraction.
Article titleWhen Will Iambic Therapeutics IPO? $15 to $17 Proposed RangeMain page topic.
Attached public sources3Number of citation links rendered at the bottom of the article.
Segmara listed companies148Live private-company listings in the public catalogue.
Priced listings37Catalogue listings with visible indicative or direct marks.
Listings without an indicative price111Catalogue listings where a public price is intentionally not invented.
CompanyIambic TherapeuticsNamed company covered by this page.
Symbol labelIAMBSegmara display symbol; not a public stock ticker unless separately stated.
SectorAI Drug DiscoveryCatalogue sector used for comparison and internal linking.
Listing structureRequestHow the listing is categorized on Segmara.
Segmara markNo indicative price yetVisible listing mark, or no indicative price yet.
Sector peer count2Number of live Segmara listings in AI Drug Discovery.
Structure peer count111Number of live Segmara listings categorized as Request.
StageTimingPrice / valuation signalInterpretation
FormationPrivateEarly ownershipThe first value creation happens before ordinary public-market access.
Growth roundsPrivateInstitutional repricingLater rounds and tenders create the price history buyers study.
Segmara listingCurrentNo indicative price yetIndicative reference only, not a quote or an offer.
Exit pathFutureIPO, tender, acquisition, or continued private statusLiquidity timing remains company-specific.
Chart metricScoreInterpretation
Start Iambic Therapeutics from $25 →

Analytical lens

Search intent

Searches like 'When Will Iambic Therapeutics IPO? $15 to $17 Proposed Range' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.

What counts as a listing step

For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.

Segmara role

Segmara takes reviewed pre-IPO allocation requests funded by Stripe USD credits from $25 ($1.00 starter credit); no allocation is guaranteed. It also publishes dated indicative reference marks across 140+ private companies. Nothing on this page is investment advice.

How pre-IPO share access works

Standard Segmara allocation path

1. SearchStart with the company or pre-IPO question
2. ListingReview indicative mark and structure context
3. CheckoutFund from $25 ($1 starter credit) via Stripe, no password
4. ReviewEach request is reviewed in your dashboard; no allocation is guaranteed

What happens after payment

Indicative mark & listing selectionPublic
No-password StripeFrom $25 / $1 credit
Share allocation requestDirect
Transfer & settlement termsReviewed, not guaranteed
Start Iambic Therapeutics from $25 →

Key takeaways

Risk notes

Public source links

PRE-IPO ALLOCATION

Request Iambic Therapeutics pre-IPO shares

Start from $25 in USD portfolio credits via Stripe (no password required) and request a pre-IPO share allocation in Iambic Therapeutics.

Start Iambic Therapeutics from $25 →

1-unit requests under $20: Aalo ($1.00) · ID.me ($1.40) · Chainalysis ($6.20) · Precision ($8.18) · Scale AI ($8.78) · Huntress ($19.03)

Explore all pre-IPO listingsFund portfolio credits

Questions

Can investors request private-company shares on Segmara?

Yes. Start from $25 ($1.00 starter credit available) in USD portfolio credits via Stripe with no password required, or select a listing across 140+ private companies on Segmara to submit a pre-IPO share allocation request.

Why was this market historically hard for individual investors to reach?

Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: browse 140+ named private-company listings, fund USD credits via Stripe from $25 ($1.00 starter credit), and request share allocations with no password wall.

What is the easiest next step?

Start from $25 ($1.00 starter credit available) via instant Stripe checkout (Card, Apple Pay, Link, no password required), or browse Segmara's live pre-IPO listings to select your target company.

Has Iambic Therapeutics set an IPO date?

The October 8, 2026 preliminary prospectus does not specify a share-delivery date or final IPO price. It proposes a $15 to $17 range, but that does not confirm a first trading date.

What is Iambic's proposed IPO price?

The October 8 amended S-1 proposes 9,375,000 shares at $15 to $17 per share. Those terms are preliminary and may change; the $16 midpoint is an assumption used in the filing's estimates, not a final price.

What stage is IAM1363 in?

The amended S-1 describes an ongoing Phase 1/1b basket trial in advanced HER2-altered solid tumors. Iambic anticipates a registrational trial as early as 2027, subject to regulatory feedback.

Can I buy Iambic Therapeutics shares through Segmara?

Yes. Iambic Therapeutics has filed an amended Form S-1 proposing $15 to $17 per share under Nasdaq ticker IAM, without commencing public exchange trading yet. On Segmara, you can start an Iambic Therapeutics pre-IPO allocation request from $25 ($1.00 starter credit, no password upfront) via Stripe checkout, or request 1 full Precision Neuroscience share at $8.18/sh alongside Aspen Neuroscience and Isomorphic Labs.

Pre-IPO Allocation

Request Iambic Therapeutics shares on Segmara.

Start from $25 ($1 starter credit available) via Stripe with no password required, fund USD portfolio credits, and request a pre-IPO allocation in Iambic Therapeutics.

Request Iambic Therapeutics Allocation →

1-unit requests under $20: Aalo ($1.00) · ID.me ($1.40) · Chainalysis ($6.20) · Precision ($8.18) · Scale AI ($8.78) · Huntress ($19.03)

Explore 140+ pre-IPO listings · Custom credit amount

Start Iambic Therapeutics from $25 →